Loading
EA
Elekta AB Stock: price and insider trades · Sweden
ISIN SE0004548030SE·
No insider purchase over the last 90 days. The latest, by Gustaf Nils Philip Salford, was filed 02 Dec 2020.
Elekta AB: what insiders have been doing
Elekta AB is a listed company. Its directors and officers file their transactions with Finansinspektionen. Nothing new has been filed by managers of Elekta AB in twelve months, the latest record being from 2 December 2020.
Our records for Elekta AB go back to 2017, with 17 purchases and 4 sales on the open market in total.
Other companies in the same market with recent insider buying flagged by our signals: Dynavox Group AB and Rusta AB (publ). This summary is built from Finansinspektionen disclosures alone and does not predict where the share price will go.
Insider Decl.
30
Thresholds
n/a
Buy Volume
€8M
17 ops. · all time
Sell Volume
€12M
4 ops. · all time
Since the insiders bought
- -1.9%Entry 109.60 · Close at T+365 107.50
- -5.9%Entry 116.15 · Close at T+365 109.35
- -6.4%Entry 125.00 · Close at T+365 117.00
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Financial data
· cache
Last declaration on 2 December 2020
Declarations30 total
4,400 shares@ SEK 115.6048.9% of flowAktieISIN SE0000163628FI:csv-c6bd2c89c68489c980b9
Canonical exit: 2 Mar 2021 (T+90)
2,000 shares@ SEK 106.95100.0% of flowAktieISIN SE0000163628FI:csv-9ca5c393baf39d22dbc3
Canonical exit: 24 Feb 2021 (T+90)
5,000 shares@ SEK 107.0051.1% of flowAktieISIN SE0000163628FI:csv-f6ad7bd733aae2b8dd7a
Canonical exit: 29 Nov 2020 (T+90)
6,466 shares@ SEK 120.5036.7% of flowAktieISIN SE0000163628FI:csv-08448133456b069bbbc9
11,216 shares@ SEK 121.00100.0% of flowAktieISIN SE0000163628FI:csv-915ba3d27f693f1717c8
22,431 shares@ SEK 130.949390.6% of flowAktieFI:csv-6c822a30177443325c3b
11,216 shares@ SEK 124.0563.3% of flowAktieISIN SE0000163628FI:csv-81f8e4ab0b5bb68df37a
Canonical exit: 14 Jan 2020 (T+90)
2,400 shares@ SEK 127.23329.4% of flowAktieFI:csv-4ced8443d87c4e4a2068
Canonical exit: 1 Dec 2019 (T+90)
1,000 shares@ SEK 128.50100.0% of flowAktieISIN SE0000163628FI:csv-7fcd645d8c1300d10eb2
Canonical exit: 21 Nov 2019 (T+90)
71 shares@ SEK 109.700.0% of flowAktieISIN SE0000163628FI:csv-b1ff8202be945b4dffc4
Canonical exit: 27 May 2019 (T+90)
342 shares@ SEK 109.700.0% of flowAktieISIN SE0000163628FI:csv-ed08031e9bab2697d82c
Canonical exit: 27 May 2019 (T+90)
2,381 shares@ SEK 109.740.0% of flowAktieISIN SE0000163628FI:csv-2ad922fa1d7000b0f15a
Canonical exit: 27 May 2019 (T+90)
361 shares@ SEK 108.850.0% of flowAktieISIN SE0000163628FI:csv-9ff01463f50f9d63210b
Canonical exit: 27 May 2019 (T+90)
6,637 shares@ SEK 109.000.0% of flowAktieISIN SE0000163628FI:csv-4d4b645750aed287a561
Canonical exit: 27 May 2019 (T+90)
208 shares@ SEK 109.000.0% of flowAktieISIN SE0000163628FI:csv-e538d237ad091bedc193
Canonical exit: 27 May 2019 (T+90)
10,000 shares@ SEK 109.000.0% of flowAktieISIN SE0000163628FI:csv-23657a106af39a7e1648
Canonical exit: 27 May 2019 (T+90)
8,500 shares@ SEK 118.737354.5% of flowISIN SE0000163628FI:csv-8bc1263af37867ad016e
Canonical exit: 29 Nov 2018 (T+90)
1,000 shares@ SEK 20,000.009.4% of flowISIN SE0000163628FI:csv-542ede7eec2fa01eef9b
800,000 shares@ SEK 116.1743.7% of flowISIN SE0000163628FI:csv-7da4add1faa43640bc42
10,000 shares@ SEK 66.788197.0% of flowISIN SE0000163628FI:csv-ed7d013da99005b3033a
Canonical exit: 21 Mar 2018 (T+90)
9,500 shares@ SEK 80.824745.5% of flowISIN SE0000163628FI:csv-11c60828376e04c8a348
Canonical exit: 27 Sept 2017 (T+90)
46,800 shares@ SEK 46.8052.6% of flowISIN SE0004548030FI:csv-3cbc4879fd4349804d49
20,000 shares@ SEK 1.003.0% of flowISIN SE0004548030FI:csv-9227d90956a9c54ac72d
13,666,420 sharesISIN SE0004548030FI:csv-cf67c4446f63181ec00f
8,347,200 sharesISIN SE0004548030FI:csv-67ccca9b9c848de7d27f
25 of 30 declarations
About Elekta AB
Elekta AB is a Swedish company specializing in solutions for cancer treatment and neurological disorders. It develops radiotherapy and radiosurgery technologies to enhance patient care.
Recent ranked signals on the same market
Purchases our model currently ranks for the recommendations list.
All recommendations